Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Equity

Contineum Therapeutics (CTNM) Equity Average (2024 - 2025)

Historic Equity Average for Contineum Therapeutics (CTNM) over the last 2 years, with Q3 2025 value amounting to $175.9 million.

  • Contineum Therapeutics' Equity Average fell 1773.8% to $175.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $175.9 million, marking a year-over-year decrease of 1773.8%. This contributed to the annual value of $65.1 million for FY2024, which is N/A changed from last year.
  • According to the latest figures from Q3 2025, Contineum Therapeutics' Equity Average is $175.9 million, which was down 1773.8% from $178.1 million recorded in Q2 2025.
  • Over the past 5 years, Contineum Therapeutics' Equity Average peaked at $213.9 million during Q3 2024, and registered a low of -$71.8 million during Q1 2024.